The spending plan outlines: $11.6 million for community proposals supporting treatment; $3.8 million to put toward the county ...

CEO Chad Robins highlighted a strong year for Adaptive Biotechnologies, with MRD revenue increasing by 42% year-over-year. Key drivers included a higher gapfill rate of $2,007 for the clonoSEQ test ...

The next phase of Kilroy's big Oyster Point project is seeing interest from tech and financial services as well as biotech, ...

M&A in biotech and pharma is expected to surge in late 2024 as regulatory uncertainties ease. Discover trends, key players, and areas of high interest.

After a constitutionally required three-week recess, the Kentucky General Assembly reconvened to continue the people's business. The first and most critical order of business was passing House Bi ...

Aptar has a narrow economic moat, with durable switching costs in the Pharma business supported by intangible assets throughout the product portfolio from expertise in product regulation, design, and ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

You probably think “antibiotic resistance” means that a bacterial infection can’t be cured by any antibiotics. But the FDA ...

“Companies are realizing that investing stateside can provide more control and resilience to the drug supply chain,” says Dymowski. She cites political tensions, import and export disruptions, and ...

Exposed: Elizabeth Warren's Big Pharma Ties Raise Questions of Trust** In a revealing turn of events, Senator Elizabeth Warren's claims of being free from the influence of Big Pharma have come under ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where BridgeBio Pharma, Inc.

Gov. Ned Lamont eyed Medicaid reimbursement rates, a hospital tax restructuring and pharmaceutical costs in his biennial ...